{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,17]],"date-time":"2025-10-17T00:13:58Z","timestamp":1760660038210,"version":"build-2065373602"},"reference-count":51,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2018,8,1]],"date-time":"2018-08-01T00:00:00Z","timestamp":1533081600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2018,8,1]],"date-time":"2018-08-01T00:00:00Z","timestamp":1533081600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"funder":[{"DOI":"10.13039\/100000002","name":"National Institutes of Health","doi-asserted-by":"publisher","award":["HHSN272201400005C","HHSN272201200005C"],"award-info":[{"award-number":["HHSN272201400005C","HHSN272201200005C"]}],"id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["bmn.com","clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Current Opinion in Immunology"],"published-print":{"date-parts":[[2018,8]]},"DOI":"10.1016\/j.coi.2018.06.004","type":"journal-article","created":{"date-parts":[[2018,6,26]],"date-time":"2018-06-26T11:59:46Z","timestamp":1530014386000},"page":"203-208","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":7,"special_numbering":"C","title":["Pandemic influenza vaccines: what they have taught us about B cell immunology"],"prefix":"10.1016","volume":"53","author":[{"given":"David J","family":"Topham","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8273-730X","authenticated-orcid":false,"given":"Phuong","family":"Nguyen","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mark Y","family":"Sangster","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.coi.2018.06.004_bib0005","article-title":"Estimated influenza illnesses, medical visits, hospitalizations, and deaths averted by vaccination in the United States","author":"Rolfes","year":"2016","journal-title":"CDC"},{"key":"10.1016\/j.coi.2018.06.004_bib0010","first-page":"377","article-title":"Influenza A virus reassortment","volume":"vol 385","author":"Steel","year":"2014"},{"key":"10.1016\/j.coi.2018.06.004_bib0015","first-page":"jiy103","article-title":"A universal influenza vaccine: the strategic plan for the National Institute of Allergy and Infectious Diseases","author":"Erbelding","year":"2018","journal-title":"J Infect Dis"},{"key":"10.1016\/j.coi.2018.06.004_bib0020","doi-asserted-by":"crossref","first-page":"800","DOI":"10.1016\/j.chom.2016.05.014","article-title":"Both neutralizing and non-neutralizing human H7N9 influenza vaccine-induced monoclonal antibodies confer protection","volume":"19","author":"Henry Dunand","year":"2016","journal-title":"Cell Host Microbe"},{"key":"10.1016\/j.coi.2018.06.004_bib0025","doi-asserted-by":"crossref","DOI":"10.1038\/s41598-017-14931-7","article-title":"Natural and directed antigenic drift of the H1 influenza virus hemagglutinin stalk domain","volume":"7","author":"Anderson","year":"2017","journal-title":"Sci Rep"},{"key":"10.1016\/j.coi.2018.06.004_bib0030","doi-asserted-by":"crossref","first-page":"1937","DOI":"10.1016\/S0140-6736(00)05066-2","article-title":"Safety and antigenicity of non-adjuvanted and MF59-adjuvanted influenza A\/Duck\/Singapore\/97 (H5N3) vaccine: a randomised trial of two potential vaccines against H5N1 influenza","volume":"357","author":"Nicholson","year":"2001","journal-title":"Lancet"},{"key":"10.1016\/j.coi.2018.06.004_bib0035","doi-asserted-by":"crossref","first-page":"1732","DOI":"10.1016\/S0264-410X(00)00395-9","article-title":"Safety and immunogenicity of a recombinant hemagglutinin vaccine for H5 influenza in humans","volume":"19","author":"Treanor","year":"2001","journal-title":"Vaccine"},{"key":"10.1016\/j.coi.2018.06.004_bib0040","doi-asserted-by":"crossref","first-page":"1069","DOI":"10.1093\/infdis\/jis402","article-title":"direct comparison of an inactivated subvirion influenza A virus subtype H5N1 vaccine administered by the intradermal and intramuscular routes","volume":"206","author":"Patel","year":"2012","journal-title":"J Infect Dis"},{"key":"10.1016\/j.coi.2018.06.004_bib0045","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1038\/cr.2017.154","article-title":"Avian influenza H7N9 viruses: a rare second warning","volume":"28","author":"Subbarao","year":"2018","journal-title":"Cell Res"},{"key":"10.1016\/j.coi.2018.06.004_bib0050","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0050830","article-title":"Evaluations for in vitro correlates of immunogenicity of inactivated influenza A H5, H7 and H9 vaccines in humans","volume":"7","author":"Couch","year":"2012","journal-title":"PLoS ONE"},{"key":"10.1016\/j.coi.2018.06.004_bib0055","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0049704","article-title":"A randomized clinical trial of an inactivated avian influenza A (H7N7) vaccine","volume":"7","author":"Couch","year":"2012","journal-title":"PLoS ONE"},{"key":"10.1016\/j.coi.2018.06.004_bib0060","doi-asserted-by":"crossref","first-page":"1343","DOI":"10.1056\/NEJMoa055778","article-title":"Safety and immunogenicity of an inactivated subvirion influenza A (H5N1) vaccine","volume":"354","author":"Treanor","year":"2006","journal-title":"N Engl J Med"},{"key":"10.1016\/j.coi.2018.06.004_bib0065","doi-asserted-by":"crossref","first-page":"1135","DOI":"10.1086\/508174","article-title":"Safety and immunogenicity of nonadjuvanted and MF59-adjuvanted influenza A\/H9N2 vaccine preparations","volume":"43","author":"Atmar","year":"2006","journal-title":"Clin Infect Dis"},{"key":"10.1016\/j.coi.2018.06.004_bib0070","doi-asserted-by":"crossref","first-page":"1420","DOI":"10.1001\/jama.2014.12609","article-title":"Immunogenicity of avian influenza A\/Anhui\/01\/2005(H5N1) vaccine with MF59 adjuvant A randomized clinical trial","volume":"312","author":"Belshe","year":"2014","journal-title":"JAMA"},{"key":"10.1016\/j.coi.2018.06.004_bib0075","doi-asserted-by":"crossref","first-page":"1409","DOI":"10.1001\/jama.2014.12854","article-title":"Serological responses to an avian influenza A\/H7N9 vaccine mixed at the point-of-use with MF59 adjuvant a randomized clinical trial","volume":"312","author":"Mulligan","year":"2014","journal-title":"JAMA"},{"key":"10.1016\/j.coi.2018.06.004_sbref0080","doi-asserted-by":"crossref","first-page":"635","DOI":"10.1086\/590916","article-title":"Immune responses of healthy subjects to a single dose of intramuscular inactivated influenza A\/Vietnam\/1203\/2004 (H5N1) vaccine after priming with an antigenic variant","volume":"198","author":"Goji","year":"2008","journal-title":"J Infect Dis"},{"key":"10.1016\/j.coi.2018.06.004_bib0085","doi-asserted-by":"crossref","first-page":"907","DOI":"10.1016\/j.vaccine.2009.11.002","article-title":"B cell responses to H5 influenza HA in human subjects vaccinated with a drifted variant","volume":"28","author":"Baer","year":"2010","journal-title":"Vaccine"},{"key":"10.1016\/j.coi.2018.06.004_bib0090","doi-asserted-by":"crossref","first-page":"4953","DOI":"10.1016\/j.vaccine.2009.05.099","article-title":"Evaluation of two live attenuated cold-adapted H5N1 influenza virus vaccines in healthy adults","volume":"27","author":"Karron","year":"2009","journal-title":"Vaccine"},{"key":"10.1016\/j.coi.2018.06.004_bib0095","doi-asserted-by":"crossref","first-page":"711","DOI":"10.1086\/596558","article-title":"A live attenuated H9N2 influenza vaccine is well tolerated and immunogenic in healthy adults","volume":"199","author":"Karron","year":"2009","journal-title":"J Infect Dis"},{"key":"10.1016\/j.coi.2018.06.004_bib0100","doi-asserted-by":"crossref","first-page":"6798","DOI":"10.1016\/j.vaccine.2014.09.070","article-title":"Live attenuated H7N7 influenza vaccine primes for a vigorous antibody response to inactivated H7N7 influenza vaccine","volume":"32","author":"Babu","year":"2014","journal-title":"Vaccine"},{"key":"10.1016\/j.coi.2018.06.004_bib0105","doi-asserted-by":"crossref","first-page":"1860","DOI":"10.1093\/infdis\/jiu123","article-title":"A live attenuated influenza A(H5N1) vaccine induces long-term immunity in the absence of a primary antibody response","volume":"209","author":"Talaat","year":"2014","journal-title":"J Infect Dis"},{"key":"10.1016\/j.coi.2018.06.004_bib0110","doi-asserted-by":"crossref","first-page":"1270","DOI":"10.1093\/infdis\/jiv210","article-title":"High-affinity H7 head and stalk domain-specific antibody responses to an inactivated influenza H7N7 vaccine after priming with live attenuated influenza vaccine","volume":"212","author":"Halliley","year":"2015","journal-title":"J Infect Dis"},{"key":"10.1016\/j.coi.2018.06.004_sbref0115","doi-asserted-by":"crossref","DOI":"10.1128\/JVI.01970-17","article-title":"Intranasal live influenza vaccine priming elicits localized B cell responses in mediastinal lymph nodes","volume":"92","author":"Jegaskanda","year":"2018","journal-title":"J Virol"},{"key":"10.1016\/j.coi.2018.06.004_bib0120","doi-asserted-by":"crossref","first-page":"254","DOI":"10.1016\/j.coviro.2011.08.002","article-title":"Influenza virus vaccines: lessons from the 2009 H1N1 pandemic","volume":"1","author":"Broadbent","year":"2011","journal-title":"Curr Opin Virol"},{"key":"10.1016\/j.coi.2018.06.004_bib0125","doi-asserted-by":"crossref","first-page":"9047","DOI":"10.1073\/pnas.1118979109","article-title":"Pandemic H1N1 influenza vaccine induces a recall response in humans that favors broadly cross-reactive memory B cells","volume":"109","author":"Li","year":"2012","journal-title":"Proc Natl Acad Sci U S A"},{"key":"10.1016\/j.coi.2018.06.004_bib0130","doi-asserted-by":"crossref","first-page":"13133","DOI":"10.1073\/pnas.1414070111","article-title":"Induction of broadly cross-reactive antibody responses to the influenza HA stem region following H5N1 vaccination in humans","volume":"111","author":"Ellebedy","year":"2014","journal-title":"Proc Natl Acad Sci U S A"},{"key":"10.1016\/j.coi.2018.06.004_bib0135","doi-asserted-by":"crossref","first-page":"11931","DOI":"10.1073\/pnas.1609316113","article-title":"Epitope specificity plays a critical role in regulating antibody-dependent cell-mediated cytotoxicity against influenza A virus","volume":"113","author":"He","year":"2016","journal-title":"Proc Natl Acad Sci U S A"},{"key":"10.1016\/j.coi.2018.06.004_bib0140","doi-asserted-by":"crossref","DOI":"10.1128\/mBio.01463-17","article-title":"Influenza virus hemagglutinin stalk-specific antibodies in human serum are a surrogate marker for in vivo protection in a serum transfer mouse challenge model","volume":"8","author":"Jacobsen","year":"2017","journal-title":"MBio"},{"key":"10.1016\/j.coi.2018.06.004_bib0145","doi-asserted-by":"crossref","DOI":"10.1128\/mBio.01624-16","article-title":"Broadly neutralizing hemagglutinin stalk-specific antibodies induce potent phagocytosis of immune complexes by neutrophils in an Fc-dependent manner","volume":"7","author":"Mullarkey","year":"2016","journal-title":"MBio"},{"key":"10.1016\/j.coi.2018.06.004_bib0150","doi-asserted-by":"crossref","first-page":"1153","DOI":"10.1128\/CVI.00272-14","article-title":"An H7N1 influenza virus vaccine induces broadly reactive antibody responses against H7N9 in humans","volume":"21","author":"Krammer","year":"2014","journal-title":"Clin Vaccine Immunol"},{"key":"10.1016\/j.coi.2018.06.004_bib0155","doi-asserted-by":"crossref","first-page":"13260","DOI":"10.1128\/JVI.02133-14","article-title":"Induction of broadly reactive anti-hemagglutinin stalk antibodies by an H5N1 vaccine in humans","volume":"88","author":"Nachbagauer","year":"2014","journal-title":"J Virol"},{"key":"10.1016\/j.coi.2018.06.004_sbref0160","doi-asserted-by":"crossref","DOI":"10.1128\/mSphere.00502-17","article-title":"Vaccination with a recombinant H7 hemagglutinin-based influenza virus vaccine induces broadly reactive antibodies in humans","volume":"2","author":"Stadlbauer","year":"2017","journal-title":"mSphere"},{"key":"10.1016\/j.coi.2018.06.004_sbref0165","doi-asserted-by":"crossref","DOI":"10.1126\/sciimmunol.aan2676","article-title":"Preferential induction of cross-group influenza A hemagglutinin stem-specific memory B cells after H7N9 immunization in humans","volume":"2","author":"Andrews","year":"2017","journal-title":"Sci Immunol"},{"key":"10.1016\/j.coi.2018.06.004_bib0170","doi-asserted-by":"crossref","first-page":"1255","DOI":"10.1172\/JCI74374","article-title":"Preexisting human antibodies neutralize recently emerged H7N9 influenza strains","volume":"125","author":"Henry Dunand","year":"2015","journal-title":"J Clin Investig"},{"key":"10.1016\/j.coi.2018.06.004_bib0175","doi-asserted-by":"crossref","first-page":"418","DOI":"10.1093\/infdis\/jit180","article-title":"Prime\u2013boost interval matters: a randomized phase 1 study to identify the minimum interval necessary to observe the H5 DNA influenza vaccine priming effect","volume":"208","author":"Ledgerwood","year":"2013","journal-title":"J Infect Dis"},{"key":"10.1016\/j.coi.2018.06.004_bib0180","doi-asserted-by":"crossref","first-page":"916","DOI":"10.1016\/S1473-3099(11)70240-7","article-title":"DNA priming and influenza vaccine immunogenicity: two phase 1 open label randomised clinical trials","volume":"11","author":"Ledgerwood","year":"2011","journal-title":"Lancet Infect Dis"},{"key":"10.1016\/j.coi.2018.06.004_sbref0185","doi-asserted-by":"crossref","first-page":"413","DOI":"10.1093\/infdis\/jit178","article-title":"DNA priming prior to inactivated influenza A(H5N1) vaccination expands the antibody epitope repertoire and increases affinity maturation in a boost-interval-dependent manner in adults","volume":"208","author":"Khurana","year":"2013","journal-title":"J Infect Dis"},{"key":"10.1016\/j.coi.2018.06.004_sbref0190","doi-asserted-by":"crossref","first-page":"666","DOI":"10.1093\/infdis\/jiq093","article-title":"Safety and immunogenicity of influenza A H5 subunit vaccines: effect of vaccine schedule and antigenic variant","volume":"203","author":"Belshe","year":"2011","journal-title":"J Infect Dis"},{"key":"10.1016\/j.coi.2018.06.004_bib0195","doi-asserted-by":"crossref","first-page":"923","DOI":"10.1016\/j.vaccine.2016.12.053","article-title":"Stable emulsion (SE) alone is an effective adjuvant for a recombinant, baculovirus-expressed H5 influenza vaccine in healthy adults: a phase 2 trial","volume":"35","author":"Treanor","year":"2017","journal-title":"Vaccine"},{"key":"10.1016\/j.coi.2018.06.004_bib0200","doi-asserted-by":"crossref","first-page":"2564","DOI":"10.1056\/NEJMc1313186","article-title":"A recombinant viruslike particle influenza A (H7N9) vaccine","volume":"369","author":"Fries","year":"2013","journal-title":"N Engl J Med"},{"key":"10.1016\/j.coi.2018.06.004_bib0205","doi-asserted-by":"crossref","first-page":"64","DOI":"10.1016\/j.coi.2017.06.008","article-title":"Germinal center enhancement by extended antigen availability","volume":"47","author":"Cirelli","year":"2017","journal-title":"Curr Opin Immunol"},{"key":"10.1016\/j.coi.2018.06.004_bib0210","doi-asserted-by":"crossref","first-page":"3331","DOI":"10.1016\/j.vaccine.2009.01.084","article-title":"Mechanism of action of licensed vaccine adjuvants","volume":"27","author":"Tritto","year":"2009","journal-title":"Vaccine"},{"key":"10.1016\/j.coi.2018.06.004_bib0215","doi-asserted-by":"crossref","DOI":"10.1126\/scitranslmed.aad0522","article-title":"Immune history profoundly affects broadly protective B cell responses to influenza","volume":"7","author":"Andrews","year":"2015","journal-title":"Sci Transl Med"},{"key":"10.1016\/j.coi.2018.06.004_bib0220","doi-asserted-by":"crossref","first-page":"521","DOI":"10.1016\/j.coviro.2013.07.007","article-title":"Influenza virus hemagglutinin stalk-based antibodies and vaccines","volume":"3","author":"Krammer","year":"2013","journal-title":"Curr Opin Virol"},{"key":"10.1016\/j.coi.2018.06.004_bib0225","doi-asserted-by":"crossref","first-page":"70","DOI":"10.1016\/j.it.2017.08.003","article-title":"From original antigenic sin to the universal influenza virus vaccine","volume":"39","author":"Henry","year":"2018","journal-title":"Trends Immunol"},{"key":"10.1016\/j.coi.2018.06.004_sbref0230","doi-asserted-by":"crossref","first-page":"722","DOI":"10.1126\/science.aag1322","article-title":"Potent protection against H5N1 and H7N9 influenza via childhood hemagglutinin imprinting","volume":"354","author":"Gostic","year":"2016","journal-title":"Science"},{"key":"10.1016\/j.coi.2018.06.004_bib0235","doi-asserted-by":"crossref","first-page":"1000","DOI":"10.1016\/j.talanta.2010.11.002","article-title":"Label-free, arrayed sensing of immune response to influenza antigens","volume":"83","author":"Mace","year":"2011","journal-title":"Talanta"},{"key":"10.1016\/j.coi.2018.06.004_bib0240","doi-asserted-by":"crossref","first-page":"e0129858","DOI":"10.1371\/journal.pone.0129858","article-title":"Multi-dimensional measurement of antibody-mediated heterosubtypic immunity to influenza","volume":"10","author":"Wang","year":"2015","journal-title":"PLOS ONE"},{"key":"10.1016\/j.coi.2018.06.004_bib0245","doi-asserted-by":"crossref","first-page":"51","DOI":"10.1186\/s12859-018-2042-4","article-title":"Antigenic cartography of H1N1 influenza viruses using sequence-based antigenic distance calculation","volume":"19","author":"Anderson","year":"2018","journal-title":"BMC Bioinform"},{"key":"10.1016\/j.coi.2018.06.004_bib0250","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0188267","article-title":"Antigenicity of the 2015\u20132016 seasonal H1N1 human influenza virus HA and NA proteins","volume":"12","author":"Clark","year":"2017","journal-title":"PLOS ONE"},{"key":"10.1016\/j.coi.2018.06.004_bib0255","doi-asserted-by":"crossref","first-page":"160","DOI":"10.1111\/imm.12594","article-title":"Directed selection of influenza virus produces antigenic variants that match circulating human virus isolates and escape from vaccine-mediated immune protection","volume":"148","author":"DeDiego","year":"2016","journal-title":"Immunology"}],"container-title":["Current Opinion in Immunology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0952791517301899?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0952791517301899?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,16]],"date-time":"2025-10-16T08:47:04Z","timestamp":1760604424000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0952791517301899"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,8]]},"references-count":51,"alternative-id":["S0952791517301899"],"URL":"https:\/\/doi.org\/10.1016\/j.coi.2018.06.004","relation":{},"ISSN":["0952-7915"],"issn-type":[{"type":"print","value":"0952-7915"}],"subject":[],"published":{"date-parts":[[2018,8]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Pandemic influenza vaccines: what they have taught us about B cell immunology","name":"articletitle","label":"Article Title"},{"value":"Current Opinion in Immunology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.coi.2018.06.004","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2018 Elsevier Ltd. All rights reserved.","name":"copyright","label":"Copyright"}]}}